Tyler Dylan Hyde Net Worth

The estimated Net Worth of Tyler Dylan Hyde is at least $6.92 Milhão dollars as of 16 January 2018. Tyler Hyde owns over 66,000 units of CRISPR Therapeutics AG stock worth over $1,145,270 and over the last 8 years Tyler sold CRSP stock worth over $5,775,420.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Tyler Hyde CRSP stock SEC Form 4 insiders trading

Tyler has made over 14 trades of the CRISPR Therapeutics AG stock since 2017, according to the Form 4 filled with the SEC. Most recently Tyler sold 66,000 units of CRSP stock worth $1,849,980 on 16 January 2018.

The largest trade Tyler's ever made was selling 66,000 units of CRISPR Therapeutics AG stock on 16 January 2018 worth over $1,849,980. On average, Tyler trades about 18,000 units every 18 days since 2017. As of 16 January 2018 Tyler still owns at least 25,204 units of CRISPR Therapeutics AG stock.

You can see the complete history of Tyler Hyde stock trades at the bottom of the page.

What's Tyler Hyde's mailing address?

Tyler's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS AG, BAARERSTRASSE 14, ZUG, V8, CH-6300.

Insiders trading at CRISPR Therapeutics AG

Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, eCorp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Complete history of Tyler Hyde stock trades at CRISPR Therapeutics AG

CRISPR Therapeutics AG executives and stock owners

CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:

• Samarth Kulkarni,
  Chief Executive Officer, Director
• Lawrence Klein,
  Chief Operating Officer, Chief Business Officer
• Tony Ho,
  Executive Vice President - Research and Development
• James Kasinger,
  General Counsel, Secretary
• Michael Tomsicek,
  Chief Financial Officer
• Dr. Samarth Kulkarni,
  CEO & Director
• Dr. Lawrence Otto Klein Ph.D.,
  Chief Operating Officer
• James R. Kasinger,
  Gen. Counsel & Sec.
• Rodger Novak,
  Chairman of the Board, President, Co-Founder
• Dr. Rodger Novak M.D.,
  Founder, Chairman & Pres
• Susan Kim,
  IR Contact Officer
• Katherine High,
  Independent Director
• John Greene,
  Independent Director
• Simeon George,
  Independent Director
• Bradley Bolzon,
  Independent Director
• Ali Behbahani,
  Independent Director
• Dr. Daniel G. Anderson Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Matthew Porteus M.D., Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Chad Cowan Ph.D.,
  Scientific Founder
• Dr. Craig C. Mello Ph.D.,
  Scientific Founder & Advisory Board Member
• Dr. Emmanuelle Marie Charpentier,
  Co-Founder & Scientific Advisory Board Member
• Shaun Foy,
  Founder
• Aktiengesellschaft Bayer Gl...,
  
• Tyler Dylan Hyde,
  Chief Legal Officer
• Pablo J Cagnoni,
  Director
• Venture Capital Iv, L.P.Ver...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Kurt Von Emster,
  Director
• Sven Ante Lundberg,
  Chief Scientific Officer
• Corp /De/ Celgene,
  10% owner
• Kala Subramanian,
  See Remarks
• Thomas Woiwode,
  Director
• N Anthony Coles,
  Director
• Plc Gsk,
  10% owner
• Pharmaceuticals (Europe) Lt...,
  
• Venture Capital Iv, L.P.Ver...,
  
• Julianne Bruno,
  Chief Operating Officer
• Brendan Smith,
  Chief Financial Officer
• Venture Capital Iv, L.P.Ver...,
  
• Venture Capital V, L.P.Vers...,
  
• Naimish Patel,
  Chief Medical Officer
• Harold Edward Fleming,
  
• Maria Fardis,
  
• Sandesh Mahatme,
  
• Douglas A Treco,
  
• Christian Rommel,
  
• Phuong Khanh Morrow,
  Chief Medical Officer
• Raju Prasad,
  Chief Financial Officer